ERVMER34-1 encodes HEMO (Human Endogenous MER34 ORF), an ancient endogenous retroviral envelope protein that entered mammalian genomes over 100 million years ago. Unlike functional retroviral envelope proteins, HEMO has lost fusogenic capacity due to mutation of the canonical furin cleavage motif (CTQG instead of R-X-R/K-R) and absence of an adjacent hydrophobic fusion peptide; no fusion activity has been detected experimentally. The 563-aa precursor exists as both a membrane-anchored type I transmembrane protein (~58 kDa cell-associated SU-TM form) and a major shed/soluble ~48 kDa ectodomain released by metalloproteinase-mediated cleavage (ADAM/MMP-sensitive, blocked by Batimastat, Marimastat, GM6001) upstream of the transmembrane domain, with mass-spectrometry-mapped cleavage near Q432/R433. Membrane anchoring is required for efficient shedding. HEMO is expressed primarily in first-trimester placental cytotrophoblasts and extravillous trophoblasts, in early embryos and pluripotent stem/iPSCs, and in various tumors (notably ovarian clear-cell carcinoma and HNSCC, where it is inducible by gamma-irradiation and proposed as a pan-cancer immunotherapy target). The secreted form circulates in maternal blood at ~1-10 nM during pregnancy. HEMO is unusual among ERV-derived genes in being transcribed from a CpG-rich, non-LTR host-like promoter under epigenetic (DNA methylation) control. HEMO retains a putative immunosuppressive domain (ISD) characteristic of gamma-type retroviral envelope proteins, and a primate-specific BACE2 interaction has been reported. No validated host receptor or signaling pathway has been demonstrated; on the basis of trophoblast localization similar to ERVH48-1/Suppressyn, an anti-cell-fusion role has been hypothesized but not experimentally established. Expression in some tumors is associated with Wnt/beta-catenin pathway activation, particularly CTNNB1 mutations in endometrial cancers.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
| GO:0005576 extracellular region | IEA GO_REF:0000044 | ACCEPT | Summary: The secreted form of HEMO (48 kDa) is released into the extracellular space following cleavage upstream of the transmembrane domain (PMID:28739914). This secreted form has been detected in the blood of pregnant women. The annotation is appropriate for the secreted form of the protein. Reason: UniProt subcellular location indicates the protein has a secreted form that is released following proteolytic cleavage. The deep research confirms HEMO is actively shed in the blood circulation in humans via specific cleavage of the precursor envelope protein upstream of the transmembrane domain (PMID:28739914). GO has obsoleted GO:0005615 extracellular space and replaced it with GO:0005576, so this is the correct term for the shed form found in blood. Supporting Evidence: PMID:28739914 it is actively shed in the blood circulation in humans via specific cleavage of the precursor envelope protein upstream of the transmembrane domain file:human/ERVMER34-1/ERVMER34-1-deep-research-falcon.md Shedding is **consistent with metalloproteinase-mediated processing** and is inhibited by broad-spectrum **ADAM/MMP inhibitors** (Batimastat, Marimastat, GM6001; dose range shown ~0.1β10 ΞΌM) in transfected cells |
| GO:0005886 plasma membrane | IEA GO_REF:0000044 | ACCEPT | Summary: HEMO is a type I transmembrane protein. The protein contains a signal peptide (aa 1-26), an extracellular domain (aa 27-488), a transmembrane helix (aa 489-509), and a cytoplasmic tail (aa 510-563). The uncleaved form at the cell surface represents the major form. Reason: UniProt annotation clearly indicates HEMO is a single-pass type I membrane protein localized to the cell membrane. The protein is found at the cell surface, with evidence from the deep research confirming plasma membrane localization. Supporting Evidence: PMID:28739914 specific cleavage of the precursor envelope protein upstream of the transmembrane domain file:human/ERVMER34-1/ERVMER34-1-deep-research-falcon.md **Membrane anchoring is required** for efficient shedding: constructs truncated before the TM are not shed efficiently |
Loading supporting contentβ¦
Download this section (compressed HTML)Q: What is the receptor for secreted HEMO and what signaling pathway does it activate?
Q: What is the functional consequence of HEMO-BACE2 interaction?
Q: Does HEMO retain immunosuppressive activity through its ISD domain?
Q: What is the mechanism linking HEMO expression to Wnt/beta-catenin pathway activation in tumors?
Q: Why are HEMO blood levels highest in the first trimester?
Q: What selective pressure has maintained HEMO under purifying selection for >100 million years?
Q: Does HEMO act as an inhibitor of trophoblast cell fusion (analogous to Suppressyn/ERVH48-1), and if so via what mechanism (receptor competition, paracrine action, or another route)?
Q: Which specific ADAM/MMP-family metalloproteinase(s) cleave HEMO at Q432/R433 in vivo, and is shedding regulated developmentally or in disease?
Experiment: Receptor identification studies using secreted HEMO as bait (pull-down, proximity labeling)
Hypothesis: Secreted HEMO binds to a specific cell surface receptor to mediate signaling
Experiment: Immunosuppression assays testing HEMO ISD peptide effects on T cell activation
Hypothesis: The immunosuppressive domain of HEMO retains functional immunomodulatory activity
Experiment: BACE2 interaction studies to determine if HEMO is a substrate or regulatory partner
Hypothesis: BACE2 cleaves HEMO or HEMO modulates BACE2 activity
Experiment: HEMO knockout/knockdown in trophoblast models to assess placental function
Hypothesis: HEMO is required for normal trophoblast function or placental development
Experiment: Correlation studies of HEMO blood levels with pregnancy outcomes
Hypothesis: HEMO levels are predictive of pregnancy complications
What is not known β curated, literature-grounded statements of the open unknowns (the inverse of core functions).
Gap: The primary biological function of ERVMER34-1/HEMO remains unknown. It is unresolved whether the shed ectodomain acts through a host receptor, whether membrane-bound HEMO has a distinct cell-surface role, and what downstream signaling pathway or cellular response, if any, is triggered by either form.
OPEN BIOLOGYONTOLOGY MF_DARK
What is known: HEMO is an ancient Env-like protein under purifying selection, is expressed in trophoblasts, stem/iPS cells, and tumors, and is actively shed into maternal blood during pregnancy. It lacks detectable fusogenic activity, and the current review supports only localization and shedding, not a receptor, signaling pathway, enzymatic activity, or specific biological process.
Significance: This is the central gap for HEMO curation: the protein is clearly expressed, processed, and evolutionarily retained, but there is no informative GO molecular-function or biological-process annotation for its host role.
What would resolve it: Identify binding partners/receptors using secreted and membrane-tethered HEMO baits, then test candidate pathways by loss- and gain-of-function in trophoblast, pluripotent-stem-cell, and tumor models.
Provenance (the field's own admissions):
Gap: The proposed placental anti-fusion or immunomodulatory function of HEMO is untested. The Suppressyn-like localization and ISD-like sequence motivate hypotheses, but it is unknown whether HEMO blocks syncytin-mediated trophoblast fusion, acts through receptor interference, or suppresses maternal immune-cell activation.
OPEN BIOLOGY BP_DARK
What is known: HEMO localizes in early trophoblast lineages, is detected in pregnancy blood, has no fusion activity of its own, and retains an ISD-like motif. These data support a placental-function hypothesis, not a demonstrated molecular function or biological process.
Significance: Placental anti-fusion or immune-modulatory activity would explain why a non-fusogenic retroviral Env-like protein is retained and shed during early pregnancy, but current evidence is insufficient for GO process annotation.
What would resolve it: Test purified and cell-associated HEMO in trophoblast fusion assays, ASCT2 or other receptor-competition assays, and maternal immune-cell activation assays with ISD-mutant HEMO controls.
Provenance (the field's own admissions):
Gap: The enzyme and regulatory logic responsible for HEMO ectodomain shedding are not known. Broad ADAM/MMP inhibitor sensitivity and mapped Q432/R433 cleavage sites show metalloproteinase-sensitive processing, but do not identify the in vivo protease or explain why shedding is developmentally and disease-context regulated.
OPEN BIOLOGY RESIDUAL_SUBGAP
What is known: HEMO is released from a membrane-anchored precursor as a major soluble ectodomain detected in maternal blood, and membrane anchoring is required for efficient shedding. The unresolved part is protease identity, cleavage-site regulation, and whether shedding itself controls HEMO activity.
Significance: Shedding is the best-defined biochemical event in HEMO biology; identifying its protease would turn a localization/processing observation into a regulated pathway that can be perturbed in placental and cancer contexts.
What would resolve it: Combine targeted ADAM/MMP knockdown or CRISPR screens with Q432/R433 cleavage reporters, endogenous trophoblast models, and pregnancy or tumor samples to test protease identity and regulation.
Provenance (the field's own admissions):
Loading supporting contentβ¦
Download this section (compressed HTML)Loading supporting contentβ¦
Download this section (compressed HTML)Loading supporting contentβ¦
Download this section (compressed HTML)